<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Carbonic anhydrase (CA) II is the predominant CA isoenzyme in the brain of mammals </plain></SENT>
<SENT sid="1" pm="."><plain>We have recently developed a dual-label time-resolved immunofluorometric assay to quantify minute amounts of CA I and II in the cerebrospinal fluid (CSF) </plain></SENT>
<SENT sid="2" pm="."><plain>The present study was aimed at elucidating the clinical value of such measurements in the case of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Lumbar CSF samples were obtained from 111 patients suffering from various <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological diseases</z:e> and from 97 control patients with no specific signs of central <z:mp ids='MP_0008912'>nervous</z:mp> system diseases </plain></SENT>
<SENT sid="4" pm="."><plain>The highest CA II concentrations were found in patients with <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (median 66.5 micrograms L-1, n = 20), whereas the control patients had markedly lower values (median 7.8 micrograms L-1, n = 97) </plain></SENT>
<SENT sid="5" pm="."><plain>Relative to a reference range calculated from the control material (10.2 +/- 17.2 micrograms L-1), the sensitivity of CA II measurement in differentiating <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> was 100% </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:e sem="disease" ids="C0007787" disease_type="Disease or Syndrome" abbrv="tia|TIA|T.I.A.">transient ischaemic attack</z:e> (median 11.2 micrograms L-1, n = 9), multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> (median 14.7 micrograms L-1, n = 18) or <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> (median 20.3 micrograms L-1, n = 17) usually had CA II concentrations within the <z:mpath ids='MPATH_458'>normal</z:mpath> range, but those with central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (n = 14), <z:hpo ids='HP_0000726'>dementia</z:hpo> (n = 19) or <z:hpo ids='HP_0100661'>trigeminal neuralgia</z:hpo> (n = 6) tended to have higher CA II levels in their CSF, the median values being 39.1 micrograms L-1, 45.5 micrograms L-1 and 44.0 micrograms L-1 respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The findings indicate that the concentration of CA II in the CSF marks disease activity in patients with brain damage </plain></SENT>
<SENT sid="8" pm="."><plain>This finding could provide a basis for further studies estimating the value of CA II measurement as a new laboratory marker of diseases affecting the brain </plain></SENT>
</text></document>